{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T06:02:49Z","timestamp":1793772169553,"version":"4.6.1"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001381","name":"National Research Foundation","doi-asserted-by":"publisher","award":["H22J1a0050"],"award-info":[{"award-number":["H22J1a0050"]}],"id":[{"id":"10.13039\/501100001381","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001381","name":"National Research Foundation","doi-asserted-by":"publisher","award":["CRP27-2021-0038"],"award-info":[{"award-number":["CRP27-2021-0038"]}],"id":[{"id":"10.13039\/501100001381","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001348","name":"A*STAR Research Entities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001348","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.jconrel.2025.01.071","type":"journal-article","created":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T00:28:30Z","timestamp":1738715310000},"page":"108-124","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":83,"special_numbering":"C","title":["Role of PEGylated lipid in lipid nanoparticle formulation for in vitro and in vivo delivery of mRNA vaccines"],"prefix":"10.1016","volume":"380","author":[{"given":"Li","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon Yi Loong","family":"Seow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki Hyun","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuo-Chieh","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi Yan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jconrel.2025.01.071_bb0005","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1021\/acs.nanolett.3c03509","article-title":"Predictive high-throughput platform for dual screening of mRNA lipid nanoparticle blood-brain barrier transfection and crossing","volume":"24","author":"Han","year":"2024","journal-title":"Nano Lett."},{"key":"10.1016\/j.jconrel.2025.01.071_bb0010","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.jconrel.2022.10.050","article-title":"Nano drug delivery systems for antisense oligonucleotides (ASO) therapeutics","volume":"352","author":"Ramasamy","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.01.071_bb0015","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.addr.2020.06.002","article-title":"Lipid nanoparticles for nucleic acid delivery: current perspectives","volume":"154-155","author":"Samaridou","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"3","key":"10.1016\/j.jconrel.2025.01.071_bb0020","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1021\/acsnanoscienceau.2c00062","article-title":"Recent advances in site-specific lipid nanoparticles for mRNA delivery","volume":"3","author":"Xu","year":"2023","journal-title":"ACS Nanosci. Au"},{"key":"10.1016\/j.jconrel.2025.01.071_bb0025","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.jconrel.2022.03.032","article-title":"mRNA vaccines for COVID-19 and diverse diseases","volume":"345","author":"Hussain","year":"2022","journal-title":"J. Control. Release"},{"issue":"3","key":"10.1016\/j.jconrel.2025.01.071_bb0030","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.xphs.2022.09.014","article-title":"The race to develop the Pfizer-BioNTech COVID-19 vaccine: from the pharmaceutical scientists\u2019 perspective","volume":"112","author":"Lewis","year":"2023","journal-title":"J. Pharm. Sci."},{"issue":"5","key":"10.1016\/j.jconrel.2025.01.071_bb0035","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1016\/j.ymthe.2022.02.001","article-title":"Lyophilization provides long-term stability for a lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine","volume":"30","author":"Muramatsu","year":"2022","journal-title":"Mol. Ther."},{"issue":"7","key":"10.1016\/j.jconrel.2025.01.071_bb0040","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1021\/acsptsci.3c00047","article-title":"Messenger RNA-based therapeutics and vaccines: what's beyond COVID-19?","volume":"6","author":"Li","year":"2023","journal-title":"ACS Pharmacol. Transl. Sci."},{"issue":"5","key":"10.1016\/j.jconrel.2025.01.071_bb0045","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1016\/j.ymthe.2022.02.016","article-title":"COVID-19 mRNA vaccines: platforms and current developments","volume":"30","author":"Szabo","year":"2022","journal-title":"Mol. Ther."},{"issue":"5","key":"10.1016\/j.jconrel.2025.01.071_bb0050","doi-asserted-by":"crossref","first-page":"4942","DOI":"10.1021\/acsnano.2c12420","article-title":"Use of a liver-targeting immune-tolerogenic mRNA lipid nanoparticle platform to treat peanut-induced anaphylaxis by single- and multiple-epitope nucleotide sequence delivery","volume":"17","author":"Xu","year":"2023","journal-title":"ACS Nano"},{"issue":"2","key":"10.1016\/j.jconrel.2025.01.071_bb0055","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41577-020-00479-7","article-title":"A guide to vaccinology: from basic principles to new developments","volume":"21","author":"Pollard","year":"2021","journal-title":"Nat. Rev. Immunol."},{"issue":"11","key":"10.1016\/j.jconrel.2025.01.071_bb0060","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1016\/j.ymthe.2021.06.004","article-title":"Highly efficient CD4+ T cell targeting and genetic recombination using engineered CD4+ cell-homing mRNA-LNPs","volume":"29","author":"Tombacz","year":"2021","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.jconrel.2025.01.071_bb0065","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41596-022-00755-x","article-title":"Preparation of selective organ-targeting (SORT) lipid nanoparticles (LNPs) using multiple technical methods for tissue-specific mRNA delivery","volume":"18","author":"Wang","year":"2023","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.jconrel.2025.01.071_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejpb.2024.114266","article-title":"Lipid nanoparticles for local delivery of mRNA to the respiratory tract: effect of PEG-lipid content and administration route","volume":"198","author":"Ongun","year":"2024","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2025.01.071_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.114990","article-title":"Lipid nanoparticles (LNPs) for in vivo RNA delivery and their breakthrough technology for future applications","volume":"200","author":"Jeong","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2025.01.071_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2023.122243","article-title":"Understanding structure activity relationships of good HEPES lipids for lipid nanoparticle mRNA vaccine applications","volume":"301","author":"Goldman","year":"2023","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2025.01.071_bb0085","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jconrel.2024.06.023","article-title":"Lipid nanoparticle (LNP) mediated mRNA delivery in cardiovascular diseases: advances in genome editing and CAR T cell therapy","volume":"372","author":"Soroudi","year":"2024","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.01.071_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.115044","article-title":"The interplay between PEGylated nanoparticles and blood immune system","volume":"200","author":"Guo","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2025.01.071_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119792","article-title":"PEG shedding-rate-dependent blood clearance of PEGylated lipid nanoparticles in mice: faster PEG shedding attenuates anti-PEG IgM production","volume":"588","author":"Suzuki","year":"2020","journal-title":"Int. J. Pharm."},{"issue":"sup1","key":"10.1016\/j.jconrel.2025.01.071_bb0100","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1080\/10717544.2017.1388451","article-title":"Cleavable PEGylation: a strategy for overcoming the \"PEG dilemma\" in efficient drug delivery","volume":"24","author":"Fang","year":"2017","journal-title":"Drug Deliv."},{"key":"10.1016\/j.jconrel.2025.01.071_bb0105","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1021\/acs.bioconjchem.3c00174","article-title":"PEGylated lipid nanoparticle formulations: immunological safety and efficiency perspective","volume":"34","author":"Tenchov","year":"2023","journal-title":"Bioconjug. Chem."},{"issue":"10","key":"10.1016\/j.jconrel.2025.01.071_bb0110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0241006","article-title":"The effects of PEGylation on LNP based mRNA delivery to the eye","volume":"15","author":"Ryals","year":"2020","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.jconrel.2025.01.071_bb0115","doi-asserted-by":"crossref","first-page":"597","DOI":"10.3390\/pharmaceutics15020597","article-title":"Effect of PEG anchor and serum on lipid nanoparticles: development of a nanoparticles tracking method","volume":"15","author":"Berger","year":"2023","journal-title":"Pharmaceutics"},{"issue":"11","key":"10.1016\/j.jconrel.2025.01.071_bb0120","doi-asserted-by":"crossref","first-page":"16982","DOI":"10.1021\/acsnano.1c04996","article-title":"Lipid nanoparticles-from liposomes to mRNA vaccine delivery, a landscape of research diversity and advancement","volume":"15","author":"Tenchov","year":"2021","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2025.01.071_bb0125","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.actbio.2021.03.055","article-title":"Liposome technologies towards colorectal cancer therapeutics","volume":"127","author":"Sang","year":"2021","journal-title":"Acta Biomater."},{"issue":"12","key":"10.1016\/j.jconrel.2025.01.071_bb0130","doi-asserted-by":"crossref","first-page":"4238","DOI":"10.1039\/D2BM01846B","article-title":"Analysis of PEG-lipid anchor length on lipid nanoparticle pharmacokinetics and activity in a mouse model of traumatic brain injury","volume":"11","author":"Waggoner","year":"2023","journal-title":"Biomater. Sci."},{"issue":"9","key":"10.1016\/j.jconrel.2025.01.071_bb0135","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1039\/D1NA00712B","article-title":"Predictive high-throughput screening of PEGylated lipids in oligonucleotide-loaded lipid nanoparticles for neuronal gene silencing","volume":"4","author":"Sarode","year":"2022","journal-title":"Nanoscale Adv."},{"key":"10.1016\/j.jconrel.2025.01.071_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.122896","article-title":"Influence of lipid composition of messenger RNA-loaded lipid nanoparticles on the protein expression via intratracheal administration in mice","volume":"637","author":"Geng","year":"2023","journal-title":"Int. J. Pharm."},{"issue":"52","key":"10.1016\/j.jconrel.2025.01.071_bb0145","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2109256118","article-title":"On the mechanism of tissue-specific mRNA delivery by selective organ targeting nanoparticles","volume":"118","author":"Dilliard","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.jconrel.2025.01.071_bb0150","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jconrel.2023.07.058","article-title":"The interplay of quaternary ammonium lipid structure and protein corona on lung-specific mRNA delivery by selective organ targeting (SORT) nanoparticles","volume":"361","author":"Dilliard","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.01.071_bb0155","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.biomaterials.2017.02.027","article-title":"Highly potent antimicrobial polyionenes with rapid killing kinetics, skin biocompatibility and in vivo bactericidal activity","volume":"127","author":"Liu","year":"2017","journal-title":"Biomaterials"},{"issue":"8","key":"10.1016\/j.jconrel.2025.01.071_bb0160","doi-asserted-by":"crossref","first-page":"11769","DOI":"10.1021\/acsnano.2c04543","article-title":"Anti-PEG antibodies boosted in humans by SARS-CoV-2 lipid nanoparticle mRNA vaccine","volume":"16","author":"Ju","year":"2022","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2025.01.071_bb0165","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jconrel.2022.02.017","article-title":"Microfluidic technologies and devices for lipid nanoparticle-based RNA delivery","volume":"344","author":"Maeki","year":"2022","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.jconrel.2025.01.071_bb0170","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1038\/s41467-020-16248-y","article-title":"Synergistic lipid compositions for albumin receptor mediated delivery of mRNA to the liver","volume":"11","author":"Miao","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2025.01.071_bb0175","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jconrel.2023.08.053","article-title":"Peptide delivery of a multivalent mRNA SARS-CoV-2 vaccine","volume":"362","author":"McCrudden","year":"2023","journal-title":"J. Control. Release"},{"issue":"5","key":"10.1016\/j.jconrel.2025.01.071_bb0180","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1039\/c3nr05559k","article-title":"Effect of polyethyleneglycol (PEG) chain length on the bio-nano-interactions between PEGylated lipid nanoparticles and biological fluids: from nanostructure to uptake in cancer cells","volume":"6","author":"Pozzi","year":"2014","journal-title":"Nanoscale"},{"key":"10.1016\/j.jconrel.2025.01.071_bb0185","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jconrel.2021.05.021","article-title":"Impact of lipid nanoparticle size on mRNA vaccine immunogenicity","volume":"335","author":"Hassett","year":"2021","journal-title":"J. Control. Release"},{"issue":"13","key":"10.1016\/j.jconrel.2025.01.071_bb0190","doi-asserted-by":"crossref","first-page":"5671","DOI":"10.1021\/acs.nanolett.1c01353","article-title":"Scalable mRNA and siRNA lipid nanoparticle production using a parallelized microfluidic device","volume":"21","author":"Shepherd","year":"2021","journal-title":"Nano Lett."},{"issue":"1","key":"10.1016\/j.jconrel.2025.01.071_bb0195","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1038\/s41467-020-14527-2","article-title":"Naturally-occurring cholesterol analogues in lipid nanoparticles induce polymorphic shape and enhance intracellular delivery of mRNA","volume":"11","author":"Patel","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2025.01.071_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114416","article-title":"The role of lipid components in lipid nanoparticles for vaccines and gene therapy","volume":"188","author":"Hald Albertsen","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"9","key":"10.1016\/j.jconrel.2025.01.071_bb0205","doi-asserted-by":"crossref","first-page":"14792","DOI":"10.1021\/acsnano.2c05647","article-title":"Engineering lipid nanoparticles for enhanced intracellular delivery of mRNA through inhalation","volume":"16","author":"Kim","year":"2022","journal-title":"ACS Nano"},{"issue":"9","key":"10.1016\/j.jconrel.2025.01.071_bb0210","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1002\/jbm.a.37705","article-title":"Influence of ionizable lipid tail length on lipid nanoparticle delivery of mRNA of varying length","volume":"112","author":"Mrksich","year":"2024","journal-title":"J. Biomed. Mater. Res. A"},{"key":"10.1016\/j.jconrel.2025.01.071_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2024.115190","article-title":"mRNA delivery systems for cancer immunotherapy: lipid nanoparticles and beyond","volume":"206","author":"Estape Senti","year":"2024","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2025.01.071_bb0220","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.copbio.2021.09.016","article-title":"Principles for designing an optimal mRNA lipid nanoparticle vaccine","volume":"73","author":"Kon","year":"2022","journal-title":"Curr. Opin. Biotechnol."},{"issue":"4","key":"10.1016\/j.jconrel.2025.01.071_bb0225","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1021\/jacs.2c10670","article-title":"Iterative design of ionizable lipids for intramuscular mRNA delivery","volume":"145","author":"Tilstra","year":"2023","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jconrel.2025.01.071_bb0230","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.addr.2020.06.019","article-title":"Controlling timing and location in vaccines","volume":"158","author":"Irvine","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2025.01.071_bb0235","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.actbio.2021.06.023","article-title":"From influenza to COVID-19: lipid nanoparticle mRNA vaccines at the frontiers of infectious diseases","volume":"131","author":"Pilkington","year":"2021","journal-title":"Acta Biomater."},{"key":"10.1016\/j.jconrel.2025.01.071_bb0240","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.addr.2020.06.003","article-title":"Dawn of lipid nanoparticles in lymph node targeting: potential in cancer immunotherapy","volume":"167","author":"Nakamura","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"10","key":"10.1016\/j.jconrel.2025.01.071_bb0245","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1038\/s12276-023-01086-x","article-title":"Immunogenicity of lipid nanoparticles and its impact on the efficacy of mRNA vaccines and therapeutics","volume":"55","author":"Lee","year":"2023","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.jconrel.2025.01.071_bb0250","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jconrel.2015.08.007","article-title":"Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes","volume":"217","author":"Pardi","year":"2015","journal-title":"J. Control. Release"},{"issue":"12","key":"10.1016\/j.jconrel.2025.01.071_bb0255","article-title":"Influence of polyethylene glycol lipid desorption rates on pharmacokinetics and pharmacodynamics of siRNA lipid nanoparticles","volume":"2","author":"Mui","year":"2013","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"7","key":"10.1016\/j.jconrel.2025.01.071_bb0260","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.7150\/thno.18136","article-title":"Surface de-PEGylation controls nanoparticle-mediated siRNA delivery in vitro and in vivo","volume":"7","author":"Zhu","year":"2017","journal-title":"Theranostics"},{"issue":"2","key":"10.1016\/j.jconrel.2025.01.071_bb0265","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/S0005-2736(98)00077-7","article-title":"Comparison of different hydrophobic anchors conjugated to poly(ethylene glycol): effects on the pharmacokinetics of liposomal vincristine","volume":"1372","author":"Webb","year":"1998","journal-title":"Biochim. Biophys. Acta"},{"issue":"5","key":"10.1016\/j.jconrel.2025.01.071_bb0270","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1038\/mt.2009.36","article-title":"Development of lipidoid-siRNA formulations for systemic delivery to the liver","volume":"17","author":"Akinc","year":"2009","journal-title":"Mol. Ther."},{"issue":"45","key":"10.1016\/j.jconrel.2025.01.071_bb0275","article-title":"Discovery of ketal-ester ionizable lipid nanoparticle with reduced hepatotoxicity, enhanced spleen tropism for mRNA vaccine delivery","volume":"11","author":"Lv","year":"2024","journal-title":"Adv. Sci. (Weinh)"},{"key":"10.1016\/j.jconrel.2025.01.071_bb0280","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jconrel.2023.09.003","article-title":"Accelerated blood clearance of PEGylated nanoparticles induced by PEG-based pharmaceutical excipients","volume":"363","author":"Miao","year":"2023","journal-title":"J. Control. Release"},{"issue":"3","key":"10.1016\/j.jconrel.2025.01.071_bb0285","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.xphs.2023.11.001","article-title":"Treatment-induced and pre-existing anti-peg antibodies: prevalence, clinical implications, and future perspectives","volume":"113","author":"Gaballa","year":"2024","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2025.01.071_bb0290","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jconrel.2023.06.027","article-title":"Anti-PEG IgM production induced by PEGylated liposomes as a function of administration route","volume":"360","author":"Takata","year":"2023","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.jconrel.2025.01.071_bb0295","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/s41541-023-00766-z","article-title":"Polyethylene glycol (PEG)-associated immune responses triggered by clinically relevant lipid nanoparticles in rats","volume":"8","author":"Wang","year":"2023","journal-title":"NPJ Vaccines"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925000811?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925000811?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T17:45:49Z","timestamp":1770140749000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365925000811"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":59,"alternative-id":["S0168365925000811"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.01.071","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of PEGylated lipid in lipid nanoparticle formulation for in vitro and in vivo delivery of mRNA vaccines","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.01.071","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}